Stocksigma LogoStocksigma Logo

Lupin and Sandoz Launch Biosimilar Ranibizumab Across Europe

Lupin announced on 12th Nov'26 that its commercial partner, Sandoz, launched Ranluspec (biosimilar Ranibizumab) across Europe, excluding Germany

Lupin and Sandoz Launch Biosimilar Ranibizumab Across Europe

Lupin Ltd 路 Press Release 路 12 Nov 2026, 5:08 pm

Lupin and Sandoz Launch Biosimilar Ranibizumab Across Europe Lupin announced on 12th Nov'26 that its commercial partner, Sandoz, launched Ranluspec (biosimilar Ranibizumab) across Europe, excluding Germany. The launch follows European Commission approval for vial and pre-filled syringe presentations. Ranluspec is indicated for retinal and choroidal vascular diseases, including wet age-related macular degeneration, diabetic macular edema, proliferative diabetic retinopathy, macular edema post-retinal vein occlusion, and choroidal neovascularization. The product rollout expands Lupin's biologic footprint in key European markets.

Original exchange filing (PDF)

More announcements from Lupin Ltd

All Lupin Ltd announcements